Compare Novavax Inc (NVAX) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Occidental Petroleum Corporation — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Occidental Petroleum Corporation trades at $61.06 (market cap $60.63B). The key difference: Occidental Petroleum Corporation is far larger — about 36.1× Novavax Inc's market cap, and Occidental Petroleum Corporation pays a 1.85% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | OXY | |
|---|---|---|
Market Cap | $1.68B | $60.63B |
Sector | Health | Energy |
52-Week High | $11.19 | $66.24 |
52-Week Low | $6.22 | $38.92 |
Enterprise Value | $1.26B | $79.39B |
Dividend Yield | — | 1.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
Occidental Petroleum (OXY) trades at $60.65, up 1.02% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 30.32% net income margin and 21.46% ROE, while trading at reasonable valuations (P/E 17.89, EV/EBITDA 5.59). Recent earnings beats and improving balance sheet with debt reduction to $25.32 billion support positive sentiment.
OXY presents a compelling opportunity with analyst consensus target of $68.67 (13% upside) and 50% buy ratings. Key catalysts include continued debt reduction, projected 2026 net margin expansion to 30.31%, and oil price tailwinds. Risks include oil price volatility, execution on production targets, and macroeconomic headwinds affecting energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
